Insulet Corporation (PODD)
| Market Cap | 13.81B |
| Revenue (ttm) | 1.78B |
| Net Income (ttm) | 234.00M |
| Shares Out | 70.04M |
| EPS (ttm) | 3.33 |
| PE Ratio | 59.22 |
| Forward PE | 60.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 490,916 |
| Open | 199.33 |
| Previous Close | 196.16 |
| Day's Range | 195.80 - 202.20 |
| 52-Week Range | 125.82 - 293.64 |
| Beta | 1.14 |
| Analysts | Buy |
| Price Target | 238.81 (+21.11%) |
| Earnings Date | Aug 6, 2024 |
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch... [Read more]
Financial Performance
In 2023, Insulet's revenue was $1.70 billion, an increase of 30.02% compared to the previous year's $1.31 billion. Earnings were $206.30 million, an increase of 4384.78%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for PODD stock is "Buy." The 12-month stock price forecast is $238.81, which is an increase of 21.11% from the latest price.
News
Insulet's SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today shared posi...
Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...
Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today made severa...
Insulet to Present at the Jefferies Global Healthcare Conference
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management ...
Insulet misses first-quarter profit estimates as marketing costs weigh
Insulet Corp reported first-quarter profit that missed market expectations on Thursday, weighed by higher marketing expenses, sending shares of the medical device maker down 3.7% in extended trading.
Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced f...
Insulet's 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today released it...
Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced p...
Nadav Eiron Joins Crusoe as Senior Vice President of Cloud Engineering
SAN FRANCISCO--(BUSINESS WIRE)--Crusoe Energy Systems LLC (“Crusoe”) announced today that Nadav Eiron has joined the company as a Senior Vice President to lead the Cloud Engineering team in Crusoe's S...
Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...
Insulet's Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented p...
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will present new ...
Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced f...
Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management ...
Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet Announces Changes to Board of Directors with Retirements and New Appointments
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...
Insulet to Announce Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced p...
Here are Wall Street's favorite stocks in the sector expected to grow profits the most in 2024
Each earnings reporting season, you can count on a flurry of articles with headlines saying companies “beat” consensus estimates for quarterly profits. But that “success” alone means nothing.
Ozempic and other weight-loss drugs' popularity set these stocks up for big gains
Investors have such high hopes for popular weight-loss medications like Wegovy and Ozempic, the wonder drugs have sent shock waves through the stock market.
3 Medical-Device Stocks Could Click in 2024
Baird is bullish on Boston Scientific, Insulet, and DexCom, stocks set to benefit as those companies ramp up sales.
Salesforce, Insulet, and Datadog Are November's Top Performers—and These Are the Worst
Salesforce is the Dow Jones Industrial Average's top-performing stock in November, while Cisco is the worst.
Insulet to Present at Upcoming Investor Conferences
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management ...
Earnings-season winners: 20 companies that have grown sales while improving profit margins
Earnings season is a time when investors like to see a “beat and raise” pattern. That is, companies report sales and earnings that surprise the market by coming in ahead of analysts' estimates.
Insulet (PODD) stock up 14% on positive earnings and growth forecast
Shares of medical device company Insulet Corporation (NASDAQ: PODD) witnessed a remarkable surge, jumping by 14% on Friday in response to the company's recent earnings report. The substantial increase...